These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Yin H; Lu Q; Wood M Mol Ther; 2008 Jan; 16(1):38-45. PubMed ID: 17968354 [TBL] [Abstract][Full Text] [Related]
28. Autologous transplantation of muscle precursor cells modified with a lentivirus for muscular dystrophy: human cells and primate models. Quenneville SP; Chapdelaine P; Skuk D; Paradis M; Goulet M; Rousseau J; Xiao X; Garcia L; Tremblay JP Mol Ther; 2007 Feb; 15(2):431-8. PubMed ID: 17235323 [TBL] [Abstract][Full Text] [Related]
29. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Wilton SD; Lloyd F; Carville K; Fletcher S; Honeyman K; Agrawal S; Kole R Neuromuscul Disord; 1999 Jul; 9(5):330-8. PubMed ID: 10407856 [TBL] [Abstract][Full Text] [Related]
30. U1 snRNA as an effective vector for stable expression of antisense molecules and for the inhibition of the splicing reaction. Martone J; De Angelis FG; Bozzoni I Methods Mol Biol; 2012; 867():239-57. PubMed ID: 22454066 [TBL] [Abstract][Full Text] [Related]
31. A canine minidystrophin is functional and therapeutic in mdx mice. Wang B; Li J; Qiao C; Chen C; Hu P; Zhu X; Zhou L; Bogan J; Kornegay J; Xiao X Gene Ther; 2008 Aug; 15(15):1099-106. PubMed ID: 18432277 [TBL] [Abstract][Full Text] [Related]
32. Dystrophin rescue by trans-splicing: a strategy for DMD genotypes not eligible for exon skipping approaches. Lorain S; Peccate C; Le Hir M; Griffith G; Philippi S; Précigout G; Mamchaoui K; Jollet A; Voit T; Garcia L Nucleic Acids Res; 2013 Sep; 41(17):8391-402. PubMed ID: 23861443 [TBL] [Abstract][Full Text] [Related]
35. Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy. Goyenvalle A; Wright J; Babbs A; Wilkins V; Garcia L; Davies KE Mol Ther; 2012 Jun; 20(6):1212-21. PubMed ID: 22354379 [TBL] [Abstract][Full Text] [Related]
36. Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Bostick B; Yue Y; Lai Y; Long C; Li D; Duan D Hum Gene Ther; 2008 Aug; 19(8):851-6. PubMed ID: 18666839 [TBL] [Abstract][Full Text] [Related]
37. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy. Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089 [TBL] [Abstract][Full Text] [Related]
38. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing. Hanson B; Wood MJA; Roberts TC RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516 [TBL] [Abstract][Full Text] [Related]
39. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Malerba A; Thorogood FC; Dickson G; Graham IR Hum Gene Ther; 2009 Sep; 20(9):955-65. PubMed ID: 19469709 [TBL] [Abstract][Full Text] [Related]
40. Revertant fibres: a possible genetic therapy for Duchenne muscular dystrophy? Wilton SD; Dye DE; Blechynden LM; Laing NG Neuromuscul Disord; 1997 Jul; 7(5):329-35. PubMed ID: 9267847 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]